{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T01:03:01Z","timestamp":1725584581884},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,10,20]],"date-time":"2010-10-20T00:00:00Z","timestamp":1287532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"},{"start":{"date-parts":[[2010,10,20]],"date-time":"2010-10-20T00:00:00Z","timestamp":1287532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s10637-010-9565-5","type":"journal-article","created":{"date-parts":[[2010,10,19]],"date-time":"2010-10-19T03:47:12Z","timestamp":1287460032000},"page":"639-646","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors"],"prefix":"10.1007","volume":"30","author":[{"given":"Isamu","family":"Okamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Tsurutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuko","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichi","family":"Fumita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiko","family":"Ohki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,20]]},"reference":[{"key":"9565_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrc905","volume":"2","author":"R Kerbel","year":"2002","unstructured":"Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727\u2013739","journal-title":"Nat Rev Cancer"},{"key":"9565_CR2","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1634\/theoncologist.11-7-753","volume":"11","author":"A Morabito","year":"2006","unstructured":"Morabito A, De Maio E, Di Maio M et al (2006) Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 11:753\u2013764","journal-title":"Oncologist"},{"key":"9565_CR3","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nrclinonc.2009.130","volume":"6","author":"SP Ivy","year":"2009","unstructured":"Ivy SP, Wick JY, Kaufman BM (2009) An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 6:569\u2013579","journal-title":"Nat Rev Clin Oncol"},{"key":"9565_CR4","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","volume":"25","author":"LQ Chow","year":"2007","unstructured":"Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884\u2013896","journal-title":"J Clin Oncol"},{"key":"9565_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2165\/11318860-000000000-00000","volume":"23","author":"GS Papaetis","year":"2009","unstructured":"Papaetis GS, Syrigos KN (2009) Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs 23:377\u2013389","journal-title":"BioDrugs"},{"key":"9565_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/978-3-642-01222-8_6","volume":"184","author":"DY Heng","year":"2010","unstructured":"Heng DY, Kollmannsberger C (2010) Sunitinib. Recent Results Cancer Res 184:71\u201382","journal-title":"Recent Results Cancer Res"},{"key":"9565_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115\u2013124","journal-title":"N Engl J Med"},{"key":"9565_CR8","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329\u20131338","journal-title":"Lancet"},{"key":"9565_CR9","unstructured":"Christensen JG, Hall C, Hollister BA (2008) Antitumor efficacy of sunitinib malate in concurrent and sequential combinations with standard chemotherapeutic agents in non-small cell lung cancer (NSCLC) nonclinical models. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; San Diego, CA. Abstract nr 1433."},{"key":"9565_CR10","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636\u20132644","journal-title":"J Clin Oncol"},{"key":"9565_CR11","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","volume":"22","author":"N Hanna","year":"2004","unstructured":"Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589\u20131597","journal-title":"J Clin Oncol"},{"key":"9565_CR12","first-page":"37","volume":"24","author":"J Walling","year":"2006","unstructured":"Walling J (2006) From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates Invest New Drugs 24:37\u201377","journal-title":"A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs"},{"issue":"Suppl 8","key":"9565_CR13","first-page":"480P","volume":"19","author":"LQM Chow","year":"2008","unstructured":"Chow LQM, Jonker DJ, Call JA et al (2008) A phase I dose-escalation study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies. Ann Oncol 19(Suppl 8):480P","journal-title":"Ann Oncol"},{"key":"9565_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"9565_CR15","doi-asserted-by":"crossref","unstructured":"Shirao K, Nishida T, Doi T et al. (2009) Phase I\/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest New Drugs Sep 3 (Epub ahead of print)","DOI":"10.1007\/s10637-009-9306-9"},{"key":"9565_CR16","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/jjco\/hyp146","volume":"40","author":"H Uemura","year":"2010","unstructured":"Uemura H, Shinohara N, Yuasa T et al (2010) A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 40:194\u2013202","journal-title":"Jpn J Clin Oncol"},{"key":"9565_CR17","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/sj.bjc.6603321","volume":"95","author":"K Nakagawa","year":"2006","unstructured":"Nakagawa K, Kudoh S, Matsui K et al (2006) A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. Br J Cancer 95:677\u2013682","journal-title":"Br J Cancer"},{"key":"9565_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","volume":"24","author":"S Faivre","year":"2006","unstructured":"Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25\u201335","journal-title":"J Clin Oncol"},{"key":"9565_CR19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00280-007-0498-4","volume":"61","author":"CD Britten","year":"2008","unstructured":"Britten CD, Kabbinavar F, Hecht JR et al (2008) A phase I and pharmacokinetic study of sunitinib administered daily for 2\u00a0weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 61:515\u2013524","journal-title":"Cancer Chemother Pharmacol"},{"key":"9565_CR20","first-page":"1011","volume":"2","author":"TJ Abrams","year":"2003","unstructured":"Abrams TJ, Murray LJ, Pesenti E et al (2003) Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with \u201cstandard of care\u201d therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2:1011\u20131021","journal-title":"Mol Cancer Ther"},{"key":"9565_CR21","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1200\/JCO.2007.14.5375","volume":"26","author":"HJ Burstein","year":"2008","unstructured":"Burstein HJ, Elias AD, Rugo HS et al (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810\u20131816","journal-title":"J Clin Oncol"},{"key":"9565_CR22","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/sj.bjc.6605346","volume":"101","author":"S Novello","year":"2009","unstructured":"Novello S, Scagliotti GV, Rosell R et al (2009) Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 101:1543\u20131548","journal-title":"Br J Cancer"},{"key":"9565_CR23","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.1200\/JCO.2008.20.5476","volume":"27","author":"B Escudier","year":"2009","unstructured":"Escudier B, Roigas J, Gillessen S et al (2009) Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4068\u20134075","journal-title":"J Clin Oncol"},{"key":"9565_CR24","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/j.ejca.2009.02.011","volume":"45","author":"S George","year":"2009","unstructured":"George S, Blay JY, Casali PG et al (2009) Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45:1959\u20131968","journal-title":"Eur J Cancer"},{"key":"9565_CR25","first-page":"82","volume":"26","author":"DA Rinaldi","year":"1999","unstructured":"Rinaldi DA (1999) Overview of phase I trials of multitargeted antifolate (MTA, LY231514). Semin Oncol 26:82\u201388","journal-title":"Semin Oncol"},{"key":"9565_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s002800050992","volume":"44","author":"DA Rinaldi","year":"1999","unstructured":"Rinaldi DA, Kuhn JG, Burris HA et al (1999) A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21\u00a0days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 44:372\u2013380","journal-title":"Cancer Chemother Pharmacol"},{"key":"9565_CR27","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/annonc\/mdm592","volume":"19","author":"MH Cullen","year":"2008","unstructured":"Cullen MH, Zatloukal P, Sorenson S et al (2008) A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 19:939\u2013945","journal-title":"Ann Oncol"},{"key":"9565_CR28","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.1158\/1078-0432.CCR-07-5143","volume":"14","author":"Y Ohe","year":"2008","unstructured":"Ohe Y, Ichinose Y, Nakagawa K et al (2008) Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 14:4206\u20134212","journal-title":"Clin Cancer Res"},{"key":"9565_CR29","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1592\/phco.26.5.641","volume":"26","author":"LR Villela","year":"2006","unstructured":"Villela LR, Stanford BL, Shah SR (2006) Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy. Pharmacotherapy 26:641\u2013654","journal-title":"Pharmacotherapy"},{"key":"9565_CR30","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1097\/JTO.0b013e3181da3899","volume":"5","author":"C Tanai","year":"2010","unstructured":"Tanai C, Yamamoto N, Ohe Y et al (2010) A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancer. J Thorac Oncol 5:1068\u20131074","journal-title":"J Thorac Oncol"},{"key":"9565_CR31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1634\/theoncologist.2008-0232","volume":"14","author":"G Scagliotti","year":"2009","unstructured":"Scagliotti G, Hanna N, Fossella F et al (2009) The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 14:253\u2013263","journal-title":"Oncologist"},{"key":"9565_CR32","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1200\/JCO.2007.13.9303","volume":"26","author":"MA Socinski","year":"2008","unstructured":"Socinski MA, Novello S, Brahmer JR et al (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26:650\u2013656","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9565-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-010-9565-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10637-010-9565-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9565-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:19:24Z","timestamp":1678558764000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-010-9565-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,20]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["9565"],"URL":"https:\/\/doi.org\/10.1007\/s10637-010-9565-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,20]]},"assertion":[{"value":"10 September 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}